NasdaqGS - Delayed Quote USD

Genmab A/S (GMAB)

28.15 +0.69 (+2.51%)
At close: April 26 at 4:00 PM EDT
Currency in DKK All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
16,474,000.00
16,474,000.00
14,505,000.00
8,417,000.00
10,111,000.00
Cost of Revenue
226,000.00
226,000.00
--
--
--
Gross Profit
16,248,000.00
16,248,000.00
14,505,000.00
8,417,000.00
--
Operating Expense
10,927,000.00
10,927,000.00
8,238,000.00
5,464,000.00
3,798,000.00
Operating Income
5,321,000.00
5,321,000.00
6,267,000.00
2,953,000.00
6,313,000.00
Net Non Operating Interest Income Expense
912,000.00
912,000.00
303,000.00
184,000.00
174,000.00
Other Income Expense
-596,000.00
-596,000.00
375,000.00
781,000.00
-583,000.00
Pretax Income
5,637,000.00
5,637,000.00
6,945,000.00
3,918,000.00
5,904,000.00
Tax Provision
1,285,000.00
1,285,000.00
1,493,000.00
961,000.00
1,146,000.00
Net Income Common Stockholders
4,352,000.00
4,352,000.00
5,452,000.00
2,957,000.00
4,758,000.00
Diluted NI Available to Com Stockholders
4,352,000.00
4,352,000.00
5,452,000.00
2,957,000.00
4,758,000.00
Basic EPS
6.66
6.66
8.34
4.52
7.30
Diluted EPS
6.60
6.60
8.26
4.48
7.22
Basic Average Shares
653,097.44
653,097.44
653,873.01
653,956.37
651,790.06
Diluted Average Shares
659,147.05
659,147.05
660,096.04
660,457.51
658,858.75
Total Operating Income as Reported
5,321,000.00
5,321,000.00
6,267,000.00
2,953,000.00
6,313,000.00
Total Expenses
11,153,000.00
11,153,000.00
8,238,000.00
5,464,000.00
3,798,000.00
Net Income from Continuing & Discontinued Operation
4,352,000.00
4,352,000.00
5,452,000.00
2,957,000.00
4,758,000.00
Normalized Income
4,812,136.95
4,812,136.95
5,157,615.55
2,367,562.28
5,227,836.38
Interest Income
939,000.00
939,000.00
324,000.00
197,000.00
184,000.00
Interest Expense
27,000.00
27,000.00
21,000.00
13,000.00
10,000.00
Net Interest Income
912,000.00
912,000.00
303,000.00
184,000.00
174,000.00
EBIT
5,664,000.00
5,664,000.00
6,966,000.00
3,931,000.00
5,914,000.00
EBITDA
5,959,000.00
5,959,000.00
7,328,000.00
4,179,000.00
6,173,000.00
Reconciled Cost of Revenue
226,000.00
226,000.00
--
--
--
Reconciled Depreciation
295,000.00
295,000.00
362,000.00
248,000.00
259,000.00
Net Income from Continuing Operation Net Minority Interest
4,352,000.00
4,352,000.00
5,452,000.00
2,957,000.00
4,758,000.00
Total Unusual Items Excluding Goodwill
-596,000.00
-596,000.00
375,000.00
781,000.00
-583,000.00
Total Unusual Items
-596,000.00
-596,000.00
375,000.00
781,000.00
-583,000.00
Normalized EBITDA
6,555,000.00
6,555,000.00
6,953,000.00
3,398,000.00
6,756,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-135,863.05
-135,863.05
80,615.55
191,562.28
-113,163.62
12/31/2020 - 6/1/2009

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

LEGN Legend Biotech Corporation
45.30
+1.98%
 
ARGX argenx SE
372.80
+1.14%
 
INCY Incyte Corporation
51.68
+0.98%
 
ASND Ascendis Pharma A/S
135.90
-0.75%
 
HALO Halozyme Therapeutics, Inc.
38.57
+0.29%
 
RPRX Royalty Pharma plc
28.00
-0.39%
 
BGNE BeiGene, Ltd.
153.58
+3.38%
 
UTHR United Therapeutics Corporation
233.85
-0.89%
 
PCVX Vaxcyte, Inc.
60.72
+1.10%
 
IONS Ionis Pharmaceuticals, Inc.
41.59
-0.60%